VB-111 in Surgically Accessible Recurrent/Progressive GBM

Summary

This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

Timeline

Start

2020-08-01

Primary completion

2024-08-01

Completion

2024-08-01

Outcome

Outcome not reported

Stopped: “Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111 development program.”

Drugs

Indications